241 related articles for article (PubMed ID: 32132451)
1. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease.
Mak LY; Tong TSM; Cheung KS; Chen LJ; Lui KL; Lau KS; Leung WK
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00138. PubMed ID: 32132451
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
3. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
[TBL] [Abstract][Full Text] [Related]
5. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
[TBL] [Abstract][Full Text] [Related]
6. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
Suárez Ferrer C; Abadía Barno M; Martín Arranz E; Jochems A; García Ramírez L; Poza Cordón J; Jaquotot Herranz M; Cerpa Arencibia A; Martín Arranz MD
Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
[TBL] [Abstract][Full Text] [Related]
7. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
8. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.
Ishida N; Higuchi T; Miyazu T; Tamura S; Tani S; Yamade M; Iwaizumi M; Hamaya Y; Osawa S; Furuta T; Sugimoto K
Sci Rep; 2021 Jun; 11(1):12431. PubMed ID: 34127687
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
D'Haens G; Kelly O; Battat R; Silverberg MS; Laharie D; Louis E; Savarino E; Bodini G; Yarur A; Boland BS; Afif W; Li XJ; Hale M; Ho J; Kondragunta V; Huang B; Kuy C; Okada L; Hester KD; Bray KR; Mimms L; Jain A; Singh S; Collins A; Valasek MA; Sandborn WJ; Vermeire S; Dulai PS
Gastroenterology; 2020 Feb; 158(3):515-526.e10. PubMed ID: 31711925
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
[TBL] [Abstract][Full Text] [Related]
15. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
[TBL] [Abstract][Full Text] [Related]
16. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Renzulli P; Seibold F
Inflamm Bowel Dis; 2009 Dec; 15(12):1851-8. PubMed ID: 19462421
[TBL] [Abstract][Full Text] [Related]
17. Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis.
Nakov R; Velikova T; Nakov V; Ianiro G; Gerova V; Tankova L
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):788-794. PubMed ID: 30720187
[TBL] [Abstract][Full Text] [Related]
18. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease.
Daniluk U; Daniluk J; Krasnodebska M; Lotowska JM; Sobaniec-Lotowska ME; Lebensztejn DM
Adv Med Sci; 2019 Mar; 64(1):9-14. PubMed ID: 30237086
[TBL] [Abstract][Full Text] [Related]
19. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
20. Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease.
Pinto-Lopes P; Melo F; Afonso J; Pinto-Lopes R; Rocha C; Melo D; Macedo G; Dias CC; Carneiro F; Magro F;
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00320. PubMed ID: 33704099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
